

Agenda – COMPREHENSIVE GENE PROFILING, MOLECULAR TUMOR BOARD (MTB) AND ARTIFICIAL INTELLIGENCE IN THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH RARE ADULT CANCERS

Venue: Medisiina D and conference room Lauren 2, Kiinamyllynkatu 10, Turku, Finland, and Sokos Hotel Kupittaa, Joukahaisenkatu 6, Turku

Date: September the 29th-30th, 2022

Organizer: FICAN WEST Cancer Centre and Turku University Hospital (TYKS) and ERN-EURACAN and GENTURIS

All times are in EEST (Eastern European Summer Time)

Day 1 – Thursday, September the 29th



Time	Title, Speaker and Affiliation	Session name/Topic
9.00-9.10	Opening words by Pia Vihinen, Associate professor, FICAN West Cancer Centre	Session 1. Artificial intelligence and advances in pathological diagnostics Chairs: Prof. Markku Kallajoki and Dr. Katri Orte, MD, PhD
9.10-9.50	Cancer research with the help of real-world patient data, artificial intelligence, and deep-learning methods. Pekka Ruusuvaori, Prof., Turku Institute of Biomedicine, University of Turku	
9.50-10.20	Biobank studies helping in treatment of patients with rare cancers. Merja Perälä, PhD, Project Manager, Auria Biobank, and Eva-Maria Talvitie, MD, Turku University Hospital	
10.20.-11.00	iCAN flagship in Finland. Tomi Mäkelä, Prof., iCAN – Digital Precision Cancer Medicine Flagship, Helsinki Institute of Life Science, University of Helsinki	
11.00-12.00	Lunch break	
12.00-12.45	Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features. Edwin Cuppen, Prof., Hartwig	Session 2. Biological basics and novel technics in comprehensive gene profiling



	Medical Foundation, Amsterdam, Netherlands	Chairs: Prof. Klaus Elenius and Associate Prof. Maria Sundvall
12.45-13.30	Crowd validation of a national broad custom DNA/RNA-capture panel for precision oncology in Sweden. Johan Botling, Associate Professor of Pathology, Department of Immunology Genetics and Pathology Rudbeck Laboratory, Uppsala University Hospital, Sweden	
13.30-14.00	Artificial intelligence for image-based melanoma diagnosis. Nina Linder, MD, Associate Prof., Institute for Molecular Medicine Finland and University of Helsinki	
14.00-14.30	CIC-rearranged sarcoma and diagnostic challenges. Patient cases. Jenni Tuominen, MSc, Specializing Medical Cell Biologist, and Katri Orte, MD, PhD, Turku University Hospital and applicants	Session 3. Novel technologies in patient sampling and sample analysis Chairs: Associate Prof. Veli Kairisto and Prof. Panu Jaakkola
14.30-15.00	Coffee break	
15.00-15.30	Possibilities and limitations of clinical liquid biopsy testing. Niels Pallisgaard, Prof. Sjællands Universitetshospital, Roskilde, Denmark	
15.30-16.00	Usefulness of liquid biopsy in treatment and follow-up of cancer patients. Juha Kononen, Chief Clinical Director, Docrates Cancer Center, Helsinki	
16.00-16.45	2 patient cases presented by applicants (30 min) and discussion	
16.45-17.15	Precision oncology using ex vivo technology: a step towards individualized cancer care? Noora Nykänen, MSc, Specializing Medical Cell Biologist, University of Jyväskylä, Finland	
18.00	<i>End of the day 1</i>	
20.00	<i>Dinner at Restaurant Grädda</i>	

	<i>(Invited participants)</i>	
--	-------------------------------	--

Day 2 - Friday, September the 30th.

Time	Speaker and Affiliation	Session name/Topic
9.00-9.45	Functional precision medicine. Olli Kallioniemi, Prof., SciLifeLab & Karolinska Institutet and FIMM, University of Helsinki	 <p>Session 4. Bringing precision medicine to patients Chairs: Dr. Eva-Maria Talvitie and Dr. Katri Orte</p>
9.45-10.30	Lessons learned from Drug rediscovery program trials (DRUP) and precision medicine schemes what next? Ilse Spiekman, DRUP study coordinator, Netherlands Cancer Institute, Amsterdam Netherlands	
10.30-10.50	Arrangement and function of MTB at FICAN West Cancer Centre and importance of Finprove study in Finland. Erika Alanne, MD, PhD FICAN West Cancer Centre and Turku University Hospital	
10.50-11.10 (virtual)	Genetic counselling in patients with rare hereditary cancers. Kerry Kingham MS, CGC, Certified Genetic Counselor, Lead, Clinical Assistant Professor of Pediatrics, Cancer Genetics and Genomics, Stanford Cancer Center, USA	
11.10-12.00	Lunch break	
12.00-12.30	Experiences with arrangement of a national precision cancer medicine implementation initiative. Kjetil Tasken, Prof., Institute of Clinical Medicine, University of Oslo, Norway	 <p>Session 5. Optimal arrangement of Molecular Tumor Boards (MTBs) to support diagnosis of rare cancers and clinical decision-making Chairs: Dr. Erika Alanne and Dr. Maria Haanpää</p>
12.30-12.45	DRUP-like trials in the Nordics: Status of the IMPRESS-Norway study, and how to share data and improve recruitment of patients. Kjetil Tasken, Prof., Institute of Clinical Medicine, University of Oslo, Norway	



12.45-13.00	Status of Finprove study in Finland. Katriina Peltola, Chief Physician, Clinical Trial Unit, Helsinki Comprehensive Cancer Centre, Helsinki	
13.00-13.15 (virtual)	Status of ProTarget study in Denmark. Kristoffer Staal, Head of Phase I Unit, Department of Oncology, Centre for Cancer and Organ Diseases, Rigshospitalet, Copenhagen, Denmark	
13.15-13.45	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Janne Lehtiö, Prof., Inflames and Karolinska Institutet, Stockholm, Sweden	
13.45-14.15	Coffee break	
14.00-16.00	Molecular Tumor Board (participants from several institutes) and round table discussion	Session 6. MTB and patient cases Chairs: Dr. Erika Alanne and Dr. Maria Silvoniemi
16.00	Closing remarks and departure	

Organizing committee: Pia Vihinen, Erika Alanne, Heikki Minn, Klaus Elenius, Veli Kairisto, Maria Sundvall, Maria Silvoniemi, Markku Kallajoki, Katri Orte, Maria Haanpää, Eva-Maria Talvitie, Jenni Tuominen, Mervi Siekkinen, Mervi Toriseva.

